Thursday, January 17, 2019 8:30:11 AM
Have to wait to see what the possible dilution,conversion date and expense effect will be.What they do with the proceeds may have a good or bad effect on the price of the stock, using it to make great acquisition or a bad one. The only details we know at this point in time is that Aurora "proposesto offer pursuant to a private placement US$250.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes"). Aurora also intends to grant to the initial purchasers of the notes an option to purchase up to an additional US$37.5 million aggregate principal amount of notes".
If issued, there will be interest expense and cash flow effect (payment of interest) as stated "The notes will bear cash interest semi-annually at a fixed rate" when issued. Not determined yet how much but lets assume 4%, which would translate into $10 million or at 3% would be $7.5 million annually. Secondly, it is undetermined at this point in time, what the conversion date might be (before or at maturity date) and what the conversion ratio and conversion price will be. The due (maturity) date is 2024, however the final terms haven't been determined yet and will be determined by Aurora and the initial purchasers as to conversion date along with the conversion price.[/b Until the final terms are determined,the actual amount of dilution and interest expense effect is unknown.
If issued, there will be interest expense and cash flow effect (payment of interest) as stated "The notes will bear cash interest semi-annually at a fixed rate" when issued. Not determined yet how much but lets assume 4%, which would translate into $10 million or at 3% would be $7.5 million annually. Secondly, it is undetermined at this point in time, what the conversion date might be (before or at maturity date) and what the conversion ratio and conversion price will be. The due (maturity) date is 2024, however the final terms haven't been determined yet and will be determined by Aurora and the initial purchasers as to conversion date along with the conversion price.[/b Until the final terms are determined,the actual amount of dilution and interest expense effect is unknown.
Recent ACB News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/28/2026 12:15:03 PM
- Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets • PR Newswire (Canada) • 04/28/2026 10:53:00 AM
- Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets • PR Newswire (US) • 04/28/2026 10:53:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2026 08:18:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/15/2026 11:21:53 AM
- Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets • PR Newswire (Canada) • 04/15/2026 11:05:00 AM
- Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets • PR Newswire (US) • 04/15/2026 11:05:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:29:57 AM
- Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year • PR Newswire (US) • 03/30/2026 11:03:00 AM
- Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year • PR Newswire (Canada) • 03/30/2026 11:03:00 AM
- Aurora to Participate in the TD Cowen 46th Annual Health Care Conference • PR Newswire (US) • 02/17/2026 11:39:00 PM
- Aurora to Participate in the TD Cowen 46th Annual Health Care Conference • PR Newswire (Canada) • 02/17/2026 11:39:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/12/2026 09:26:03 PM
- Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis • PR Newswire (US) • 02/12/2026 09:05:00 PM
- Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis • PR Newswire (Canada) • 02/12/2026 09:05:00 PM
- Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand • PR Newswire (Canada) • 02/11/2026 12:00:00 PM
- Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand • PR Newswire (US) • 02/11/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 09:44:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 02:45:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 12:27:19 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 02/04/2026 12:10:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 12:05:38 PM
- Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program • PR Newswire (Canada) • 02/04/2026 12:00:00 PM
- Aurora Cannabis Announces Fiscal 2026 Third Quarter Results • PR Newswire (Canada) • 02/04/2026 12:00:00 PM
- Aurora Cannabis Announces Fiscal 2026 Third Quarter Results • PR Newswire (US) • 02/04/2026 12:00:00 PM
